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Purpose of the study
The objective of this study was to perform a cost-effective-
ness analysis of maraviroc therapy in patients with triple-
class drug experience and/or triple-class drug resistance in
Scotland, based on data from the MOTIVATE trials.
Methods
A Markov cohort model was developed in Excel based on
the previously published ARAMIS model [1]. Lifetime
Maraviroc (MVC) treatment plus Optimized Background
Therapy (OBT) was compared to standard OBT treatment
in patients infected with CCR5-monotropic HIV-1. Dis-
ease states were defined according to CD4 cell counts and
transition probabilities and drop-out rates were based on
the MOTIVATE trials, complemented with data from the
published literature. The model was populated with UK-
specific costs (scaled to 2007 levels) and mortality rates
for the Scottish general population. Efficacy was measured
in quality-adjusted life-years (QALYs) and the analysis
was performed from the perspective of the NHS. The base
case input values and assumptions reflect a recent reim-
bursement submission.
Summary of results
MVC was associated with an incremental gain of 1.9
QALYs and incremental costs of £29,503 compared to
standard OBT treatment, resulting in an incremental cost-
effectiveness ratio (ICER) of £15,401 per QALY. Sensitiv-
ity analyses of input parameters and model assumptions
produced ICERs in the range of £10,000–30,000.
Conclusion
The results indicated that it is potentially cost-effective to
treat patients with MVC compared to standard OBT treat-
ment in highly treatment-experienced HIV patients in
Scotland.
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